Sign in to your account
or
By signing in you agree to our
Terms & conditions
 and 
Privacy policy

Double Marker Test- First Trimester near me in Mumbai

Also referred as
Dual Marker Test
Maternal Serum Screening (MSS) - First Trimester
xyz people viewed recently
2,924+ booked recently
For women
Earliest reports in
3 days
Contains
1 test
Test price:
₹2390
₹2650
10% off
Get it at ₹2151 with coupon
Apply coupon 1MGNEWG during checkout
arrow
Know when you'll get your report
For sample collection between
6 AM - 11 AM
11 AM - 10 PM
Reporting in
3 days
discount_stamp
More offers available
Know more about this test
<font color='#864291'>Know more about this test</font>
Summary

The Double Marker Test- First Trimester also known as a dual marker test, assesses specific biomarkers in a pregnant woman’s blood. It is done during the first trimester of pregnancy, usually between 10-13 weeks. This test provides information about the risk of certain birth defects such as Down syndrome (Trisomy 21), Edward syndrome (Trisomy 18), and Patau syndrome (Trisomy 13) in the developing fetus. It is available at an affordable price in Mumbai with Tata 1mg labs.

This test measures the levels of two biomarkers in the mother’s blood: human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein A (PAPP-A). The levels of these markers, along with maternal age, gestational age, and ultrasound findings help determine the likelihood of chromosomal abnormalities in the fetus. These abnormalities can lead to various genetic conditions that can affect the baby’s growth and development. Therefore, their early detection is vital for ensuring comprehensive prenatal care and addressing potential health challenges effectively. No special preparation is required for this test. 

Samples required
Blood
Find out
Why is this test booked?
Preparation for this test
Sample Collection
Who will collect your samples?

Prenatal care is necessary to ensure a healthy pregnancy and successful childbirth. Early prenatal screenings identify potential health concerns and guide medical interventions when necessary. The Double Marker Test- First Trimester is essential for early prenatal assessment. It offers invaluable insights into the developing fetus's chromosomal health. The test primarily measures two important biomarkers in the mother’s blood—human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein A (PAPP-A). Both the markers are produced by the fetus and the placenta.

The test also checks if the baby might be at risk for certain genetic problems, especially Down syndrome and Edwards syndrome. These conditions happen when there is an extra copy of chromosome 21 or 18, respectively. They can affect a baby's physical and intellectual development. However, a Double Marker Test-First Trimester is a screening test, not a diagnostic one. It does not determine whether the baby has abnormalities. Instead, it tells whether the unborn baby is at risk of developing certain abnormalities.

The test results are reported as a risk score or probability of the fetus having a chromosomal abnormality. Test results within the expected range suggest a lower risk of chromosomal abnormalities. On the contrary, high levels may indicate a higher risk of chromosomal abnormalities and prompt further testing. Furthermore, a positive screen result (high risk) does not confirm a genetic problem. It may suggest that further testing may be needed to check the baby's health more closely. On the other hand, a negative screen result (low risk) does not guarantee the absence of fetal defects.

In combined risk assessment, the NT scan (a type of ultrasound) is also used to check for conditions like Down syndrome and Patau syndrome. This, along with the mother’s details—such as age, weight, smoking, diabetes, or IVF pregnancy—is included in the overall risk calculation. However, this test does not check for neural tube defects.

No fasting is required for this test. For this test, a duly filled Maternal Serum Screen requisition form (Annexure - CR/02) and a doctor’s prescription are mandatory. Also, provide information like maternal date of birth, last date of the last menstrual period (LMP), number of fetuses (single/twins), diabetic status, body weight in kg, and history of IVF, smoking, and trisomy 21 pregnancy. It is mandatory to keep a hard copy of the latest pregnancy ultrasound report (date of scan, CRL, NT in mm/NB, Level 1) for combined risk assessment. The double marker test is valid between 9 and 13 weeks of gestation (the ideal time for combined risk assessment is between 10 and 13 weeks). Also, tell your doctor about the medications you are taking, as certain medications can affect the results of this test and might need to be discontinued.Talk to the doctor about the specific test results. The accuracy of the results is subjective to the information provided in the screening form. This information is mandatory for combined risk assessment.

See more

The Double Marker Test- First Trimester measures two biomarkers in maternal blood associated with chromosomal abnormalities.

a) Free beta-hCG (human chorionic gonadotropin): a hormone made by the placenta shortly after a woman becomes pregnant.

b) PAPP-A (pregnancy-associated plasma protein-A): a protein made by the placenta during early pregnancy. It helps the placenta grow and function properly.

These, along with the USG marker and nuchal translucency (NT) measurement, are effective in Combined screening for Down syndrome and trisomy 13/18 in the fetus. This test only gives the risk for the presence of these chromosomal abnormalities in the developing fetus. A positive screen is not diagnostic but indicates that further evaluation should be considered.

hCG is synthesized by the placenta very early in pregnancy and can be detected in the blood 8-11 days after conception. Higher levels of hCG after 11 weeks of gestation may suggest a higher chance of the baby having Down syndrome. On the other hand, low levels indicate an increased risk for trisomy 18.

PAPP-A is a protein produced by the placenta that is needed for the implantation and maintenance of a healthy placenta (afterbirth). Low levels of PAPP-A before the 14th week of pregnancy suggest an increased risk of fetal chromosomal abnormalities.

See more

The Double Marker Test- First Trimester is done:

  • For the early risk assessment of Down, Patau, and Edward syndromes in developing fetuses.
  • In pregnant women above 35 years of age and those with a family history of birth defects and a history of insulin-dependent type 1 diabetes.
  • A duly filled Maternal Serum Screen requisition form (Annexure - CR/02) and doctor's prescription are mandatory.
  • Provide information like maternal date of birth (dd/mm/yy), last date of the last menstrual period (LMP), number of fetuses (single/twins), diabetic status, body weight in kg, and history of IVF, smoking, and Trisomy 21 pregnancy.
  • Keep a hard copy of the latest pregnancy ultrasound report (Date of scan, CRL, NT in mm/NB, Level 1) - this is mandatory for combined risk assessment.
  • The test is valid between 9 to 13 weeks of gestation (the ideal time for combined risk assessment is between 10 to 13 weeks).
The Double Marker Test- First Trimester is a prenatal screening test for pregnant women. It helps assess the risk of chromosomal abnormalities in the developing fetus. It is performed to assess the risk of potential genetic conditions such as Down syndrome and Edwards syndrome.
An NT scan is an ultrasound, and a dual marker is a blood test. Both of the tests are done during the first trimester to screen for the possible risk of chromosomal abnormalities in the unborn child.
A dual marker test is typically conducted during the first trimester of pregnancy, i.e., between weeks 9 and 13. But it is advised to get tested between 10 - 13 weeks along with NT values from the USG report as it gives Combined risk which is better.
No, it is an optional test. However, doctors often recommend it for early screening, especially for women over 35 or with a family history of genetic conditions.
If you miss the time for the Dual Marker Test, your doctor might suggest another test, like the Quad Marker Test. Quad Marker test is usually done between the 15th and 21st week of pregnancy.
No fasting is required for this test. You can schedule it at your convenience without avoiding food or water beforehand.
Yes, you can book the Double Marker Test- First Trimester in Mumbai near you with Tata 1mg Labs. The test can be booked easily, is affordable, and comes with an easy-to-understand report.
Yes, home sample collection is possible for the Double Marker Test- First Trimester in Mumbai with Tata 1mg Labs. You can also choose a date and time that suits your schedule for sample collection.
The booking process for a Dual Marker Test with Tata 1mg Labs in Mumbai is straightforward and hassle-free. Follow these steps to schedule a test online: 1). Go to the Lab Tests section on the Tata 1mg website. 2). Add your preferred test to the shopping cart. 3). Choose a time and day that works for you as long as you also take the essential prerequisites into account. 4). A confirmation notification will be sent to you with all the details once the booking is complete.
Tata 1mg Labs allows you to book tests at an affordable price in Mumbai. The Double Marker Test- First Trimester can be booked at a pocket-friendly budget of Rs. 2390.
We at Tata 1mg Labs recognize the value of prompt results. We strive to deliver test results with quick turnaround times so you can receive the information promptly. The reports of the Dual Marker Test in Mumbai are often provided in 51 hours.
Did you find information useful ?
yesYES (27)
noNO (6)

Double Marker Test- First Trimester test price for other cities

Price inBangaloreRs. 2559
Price inNew DelhiRs. 2160
Price inBhubaneshwarRs. 2279
Price inGurgaonRs. 2160
Price inNoidaRs. 2280
Book a Double Marker Test- First Trimester test at home near me
Easy online booking
Easy online booking
Search for tests and packages, book your preferred time slot and enter your address for seamless at-home lab tests.
Live tracking of phlebotomist
Live tracking of phlebotomist
Track our trained phlebotomist's real time location for seamless sample collection.
Safe Sample Collection
Safe Sample Collection
Our phlebotomists follow strict safety protocols to collect samples safely at home and on time.
Sample received at lab
Sample received at lab
Samples are transported securely to our accredited labs with world-class machines for testing by qualified experts.
Quick, Doctor-Verified Reports
Quick, Doctor-Verified Reports
Get doctor-approved reports via email and WhatsApp, with options for doctor follow-ups and AI insights.
References
  1. Wald N, Densem J, Stone R, Cheng R. The use of free beta-hCG in antenatal screening for Down's syndrome. Br J Obstet Gynaecol. 1993 Jun;100(6):550-7. [Accessed 22 Sept. 2023]. Available from:
  2. Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy-associated plasma protein A as predictors of pregnancy complications. BJOG. 2000 Oct;107(10):1265-70. [Accessed 22 Sept. 2023]. Available from:
  3. Mirsafaie M, Moghaddam-Banaem L, Kheirollahi M. The Relationship between Screening Markers in the First Trimester of Pregnancy and Chromosome Aberrations. Int J Prev Med. 2022 Apr 27;13:81. [Accessed 22 Sept. 2023]. Available from:
  4. Shah KH, Anjum A, Nair P, Bhat P, Bhat RG, Bhat S. Pregnancy-associated plasma protein A: An indicator of adverse obstetric outcomes in a South India population. Turk J Obstet Gynecol. 2020 Mar;17(1):40-45. [Accessed 22 Sept. 2023]. Available from:
  5. Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome. Indian J Clin Biochem. 2013 Jan;28(1):3-12. [Accessed 22 Sept. 2023]. Available from:
  6. Commit to Healthy Choices to Help Prevent Birth Defects [Internet]. CDC; 28 June 2023 [Accessed 22 Sept. 2023]. Available from:
  7. Infections in pregnancy that may affect your baby [Internet]. CDC; 10 March 2021 [Accessed 22 Sept. 2023]. Available from:
  8. Institute of Medicine (US) Committee on Improving Birth Outcomes; Bale JR, Stoll BJ, Lucas AO, editors. Reducing Birth Defects: Meeting the Challenge in the Developing World. Washington (DC): National Academies Press (US); 2003. 3, Interventions to Reduce the Impact of Birth Defects. [Accessed 22 Sept. 2023]. Available from:

Other tests

Contains 1 test
Samples required
Preparations
Why is this test booked?
Coupon details
Available Offers